Dr. Theresa Deisher talks about DNA extracted from dead infants
Dr. Theresa Deisher talks about BIO-Technology, DNA extracted from dead infants and and about other experiments performed on living organisms.
Theresa Deisher, Ph.D. (President, Sound Choice Pharmaceutical Institute , CEO and Managing Member, AVM Biotechnology). Dr. Deisher, an expert in the field of adult stem cell therapies and regenerative medicine, brings 18 years of experience in scientific and corporate leadership positions involving research, discovery, production and commercialization of human therapeutics. Dr. Deisher’s penchant for groundbreaking scientific discovery and her distinguished scientific research has resulted in 23 patents issued in her name. She has published numerous scientific manuscripts and is a frequent invited lecturer and guest speaker in the area of stem cell technology and regenerative medicine. Throughout her career,
Dr. Deisher has been recruited by some of the country’s top biotechnology companies, including
Genentech, Repligen, ZymoGenetics, Immunex and Amgen. She has managed and mentored undergraduate honors students, post-doctoral fellows, scientific executives and over 20 research assistants/scientists at all levels of responsibility.
Dr. Deisher graduated with honors and distinction from Stanford University, and obtained her Ph.D. in Molecular and Cellular Physiology from the Department of Molecular and Cellular Physiology, Stanford University.
Subsequent to obtaining her Ph.D from Stanford, Dr. Deisher was recruited by Repligen Corporation (Cambridge, MA) and accepted a position as Research Scientist where she managed a staff of associates and scientists and directed the development of research and clinical assays in support of Phase I and Phase II clinical trials for various Repligen developmental efforts. Additionally, Dr. Deisher was selected by Sr.
Management to participate in strategic alliance initiatives, including serving on the Repligen / Eily Lilly joint development committee